文献速递消化道肿瘤放疗姑息放疗与转移瘤

纳武利尤单抗联合局部非消融放疗治疗转移性胃癌转移淋巴结的临床疗效

Clinical efficacy of anti-PD-1 immunotherapy with localized non-ablative irradiation against metastatic lymph node in patients with metastatic gastric cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-06-02

这项探索性研究纳入16例转移性胃癌患者,评估纳武利尤单抗联合局部非消融照射(22.5 Gy/5次)一处≥2.0 cm转移淋巴结的疗效。CR、PR、SD分别为18.7%、18.7%、25.0%,中位生存10.3个月,4例无复发生存超5年。治疗前IL-1ra水平低和CD8(+)CD45RO(+)CD27(+)CD127(+) T细胞频率高者疗效更好。

要点

  • 纳武利尤单抗联合22.5 Gy/5次局部非消融放疗用于转移性胃癌转移淋巴结显示初步疗效。
  • CR率18.7%、PR率18.7%、SD率25.0%,中位生存10.3个月,4例生存超5年无复发。
  • 治疗前IL-1ra水平低和特定CD8+ T细胞频率高者总生存更好,可能为疗效预测生物标志物。

核心结论

  • 局部非消融照射转移淋巴结可能增强抗PD-1免疫治疗在转移性胃癌中的临床疗效。
  • 治疗前外周血IL-1ra水平和CD8(+)CD45RO(+)CD27(+)CD127(+) T细胞频率可能是预测该联合方案疗效的候选生物标志物。

研究设计与样本

  • 探索性研究纳入16例转移性胃癌患者,接受一处≥2.0 cm转移淋巴结的非消融照射(22.5 Gy/5次)后给予纳武利尤单抗。
  • 通过外周血细胞因子多重分析、T细胞受体库分析和流式细胞术评估与疗效相关的免疫学特征。

主要发现

  • 超过80%(13/16)患者有超过5处转移,75%(12/16)患者转移累及超过2个器官。
  • Nivo-lRT_mLN的CR率、PR率、SD率分别为18.7%、18.7%、25.0%。
  • 中位生存时间为10.3个月,4例患者无复发生存超过5年。
  • 治疗前非进展者(CR/PR/SD)较进展者(PD/NE)IL-1ra水平显著更低、CD8(+)CD45RO(+)CD27(+)CD127(+) T细胞频率显著更高。
  • CD8(+)CD45RO(+)CD27(+)CD127(+) T细胞频率高组总生存显著优于低组(p = 0.0081)。

关键数值与推荐

  • 放疗剂量与分割:22.5 Gy/5次,照射一处≥2.0 cm的转移淋巴结。
  • CR、PR、SD率分别为18.7%、18.7%、25.0%。
  • 中位生存时间10.3个月,4例生存超过5年无复发。
  • CD8(+)CD45RO(+)CD27(+)CD127(+) T细胞频率高组与低组总生存比较p = 0.0081。
  • IL-1ra水平和上述T细胞频率预测总生存的时间依赖ROC AUC p值分别为0.0193和0.0442。

临床怎么用

  • 对于转移性胃癌患者,可考虑在纳武利尤单抗治疗前对一处≥2.0 cm转移淋巴结行22.5 Gy/5次局部非消融放疗。
  • 治疗前可检测外周血IL-1ra水平和CD8(+)CD45RO(+)CD27(+)CD127(+) T细胞频率以辅助预测疗效。

局限性

  • 本研究为探索性研究,样本量仅16例,结论需进一步验证。
  • 原文未报告随机对照设计、盲法及多中心验证信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer immunotherapy combining radiotherapy and anti-PD-1 therapy is a promising treatment strategy. However, the optimal method of radiotherapy to combine with anti-PD-1 therapy has not yet been established. We investigated the clinical efficacy of combinatorial immunotherapy with nivolumab and localized non-ablative irradiation against metastatic lymph node (Nivo-lRT_mLN) in patients with metastatic gastric cancer (m-GC). MATERIALS AND METHODS: This exploratory study included 16 patients with m-GC and nivolumab was administered after non-ablative irradiation, 22.5 Gy/5fractions, on one metastatic lymph node measuring 2.0 cm or larger. We evaluated the immunological characteristics associated with the therapeutic efficacy of Nivo-lRT_mLN by multiplex analysis of cytokines, T cell receptor repertoire and flow cytometric analysis using peripheral blood samples. RESULTS: More than 80% (13 out of 16) of patients had more than 5 metastases and 75% (12 out of 16) of patients had metastases in more than 2 organs. Rate of complete response (CR), partial response (PR), and stable disease (SD) in Nivo-lRT_mLN were 18.7%, 18.7%, and 25.0%. Median survival time was 10.3 months and 4 patients survived for more than five years without recurrence. Before treatment, IL-1ra level was significantly lower and frequency of CD8(+)CD45RO(+)CD27(+)CD127(+) T cells was significantly higher in non-progressors (CR/PR/SD) compared to progressors (PD/NE) and the high group with frequency of CD8(+)CD45RO(+)CD27(+)CD127(+) T cells had significantly better overall survival (OS) than the low group (p = 0.0081). The time-dependent ROC AUC at both the level of IL-1ra and frequency of CD8(+)CD45RO(+)CD27(+)CD127(+) T cells significantly predict OS (p = 0.0193 and p = 0.0442). CONCLUSIONS: These preliminary findings indicated that localized non-ablative irradiation against metastatic lymph node has a potential to enhance the clinical efficacy of anti-PD-1 immunotherapy in patients with m-GC, and IL-1ra level and frequency of CD8(+)CD45RO(+)CD27(+)CD127(+) T cells in peripheral blood before treatment may be candidate biomarkers to predict clinical efficacy of Nivo-lRT_mLN.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mimura K, Suzuki Y, Nakajima S, et al. Clinical efficacy of anti-PD-1 immunotherapy with localized non-ablative irradiation against metastatic lymph node in patients with metastatic gastric cancer. Clin Transl Radiat Oncol. 2026. PMID: 42305415. doi:10.1016/j.ctro.2026.101212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。